• Reported GAAP EPS of $0.23 down -11.54% YoY • Reported revenue of $24.76M up 823.25% YoY • BioLife Solutions expects 2026 revenue growth of $112.5M to $115M, representing 17%-20% growth over 2025, with GAAP net income for the full year and continued expansion of adjusted EBITDA margin.
Bullish
BioLife Solutions delivered strong Q4 revenue growth and improved profitability, achieving GAAP net income. The company's biopreservation media holds over 70% market share in CGT clinical trials, supporting future growth.
Bearish
BioLife Solutions experienced gross margin compression in Q4 2025 and reported full year GAAP operating and net losses. The company's future growth remains dependent on the CGT market and biotech funding environment.